广东横琴新创益生物医药

Xinchuangyi Biomedical is a clinical-stage biotechnology company based in the Hengqin Cooperation Zone of Zhuhai, China. The company focuses on the discovery and development of innovative small molecule drugs, particularly highly selective kinase inhibitors for autoimmune diseases and oncology. Its core technology leverages structure-based drug design (SBDD) to optimize therapeutic windows and minimize off-target effects. The lead program, XCY-2002, is a highly selective TYK2 inhibitor currently undergoing Phase 1 clinical trials for the treatment of psoriasis. Additionally, the company is advancing a pipeline of candidates targeting JAK1 and other key pathways in inflammation and cancer. Xinchuangyi is backed by prominent investors including Legend Capital and local government-led investment funds.